Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Publication year range
1.
Praxis (Bern 1994) ; 88(34): 1351-6, 1999 Aug 19.
Article in French | MEDLINE | ID: mdl-10484882

ABSTRACT

Depression is the most frequent psychiatric disease associated with chronic somatic disorders. Diagnosis, however, is frequently difficult to make, due on one hand to the presence of symptoms that depression and chronic somatic disorders have in common, and on the other hand to the assumption shared by the physician and its patient that depression is a normal reaction to a somatic illness. Accurate diagnosis is nevertheless necessary in order to initiate the appropriate treatment. A review of pharmacological treatments of depression related to frequent chronic somatic disorders is presented.


Subject(s)
Antidepressive Agents/therapeutic use , Depression/drug therapy , Psychophysiologic Disorders/drug therapy , Chronic Disease , Depression/etiology , Humans , Psychophysiologic Disorders/complications
2.
Parasite Immunol ; 21(9): 461-73, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10476055

ABSTRACT

Gp63 is a major surface protein of Leishmania promastigotes. Its protective efficacy has been tested in several experimental models using different mouse strains, gp63 forms, adjuvants and routes of immunization, giving rise to conflicting results. This investigation was designed to determine whether these discrepancies could be ascribed to differing experimental procedures, and to compare gp63-induced protection with that achieved using live promastigotes. Preliminary experiments demonstrated that gp63 was an extremely potent immunogen compared to a standard antigen (ovalbumin). Protection against Leishmania major infection afforded by gp63 inoculation was studied in CBA mice. Injection of gp63 in saline, or of CFA, BCG, and C. parvum without antigen, induced significant protection. When gp63 and adjuvants were combined, results differed depending on the site of vaccination relative to that of the challenge infection. Vaccination with gp63 plus adjuvants in the tail (i.e. close to the site of infection) led to a stronger reduction of lesion size than the basal level of protection elicited by adjuvants alone, except in the case of CFA. Surprisingly however, when the antigen was injected at a distance from the site of infection (immunization in the hind foot pads, infection in the rump), the protective effect of gp63 was decreased by the adjuvants. Finally, vaccination at either site using live parasites (radioattenuated or virulent promastigotes) resulted in most instances in better protection than achieved by any protocol using gp63 and adjuvants. While anti-gp63 T cells proliferated in vitro in response to L. major-infected bone marrow-derived macrophages, they were unable to activate macrophages for parasite killing. This is in contrast with lymphocytes from mice immunized with live parasites, which both proliferated and stimulated significant killing of the microorganisms within 48 h.


Subject(s)
Adjuvants, Immunologic , Leishmania major/immunology , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/prevention & control , Metalloendopeptidases/immunology , Protozoan Vaccines/immunology , Animals , Disease Models, Animal , Leishmania major/growth & development , Leishmaniasis, Cutaneous/parasitology , Lymph Nodes/cytology , Lymph Nodes/immunology , Lymphocyte Activation , Macrophages/immunology , Macrophages/parasitology , Matched-Pair Analysis , Mice , Mice, Inbred CBA , Ovalbumin/immunology , T-Lymphocytes/immunology , Vaccination , Vaccines, Attenuated/immunology , Vaccines, Synthetic/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...